Civil construction activities, as well as installation of the first equipment, have continued during the year 2019 for the new LARAMED facility, following the scheduled program. It's worth to briefly recall here that LARAMED, which stands for LAboratory of RAdioisotopes for MEDicine is the new research center, now being established at Legnaro National Labs (LNL) which will be dedicated to develop innovative applications of nuclear physics to medicine [1]. Proposed some years ago in the framework of the SPES facility, it has now become an independent research line. Main goal of the INFN- promoted, government-funded (MIUR), award-winning (2012 and 2014) LARAMED project, is to focus research on novel radionuclides having potential interest in nuclear medicine. Although still unavailable for both scientific and clinical applications, they could play a key role in improving approaches in patients' treatment and clinical research purposes. Moreover, LARAMED will focus to seek for alternative production pathways (i.e. accelerator- driven, nuclear reaction routes) for nuclear-reactor-based conventional radionuclides already used in nuclear medicine departments into hospitals.

LARAMED Facility status report at LNL

A. Boschi;A. Duatti;P. Martini;
2020

Abstract

Civil construction activities, as well as installation of the first equipment, have continued during the year 2019 for the new LARAMED facility, following the scheduled program. It's worth to briefly recall here that LARAMED, which stands for LAboratory of RAdioisotopes for MEDicine is the new research center, now being established at Legnaro National Labs (LNL) which will be dedicated to develop innovative applications of nuclear physics to medicine [1]. Proposed some years ago in the framework of the SPES facility, it has now become an independent research line. Main goal of the INFN- promoted, government-funded (MIUR), award-winning (2012 and 2014) LARAMED project, is to focus research on novel radionuclides having potential interest in nuclear medicine. Although still unavailable for both scientific and clinical applications, they could play a key role in improving approaches in patients' treatment and clinical research purposes. Moreover, LARAMED will focus to seek for alternative production pathways (i.e. accelerator- driven, nuclear reaction routes) for nuclear-reactor-based conventional radionuclides already used in nuclear medicine departments into hospitals.
2020
Esposito, J.; Antonini, P.; Boschi, A.; Calderolla, M.; Cisternino, S.; Duatti, A.; Favaron, P.; Fiorentini, G.; Keppel, G.; Martini, P.; Maggiore, M.; Mou, L.; Pasquali, M.; Pranovi, L.; Pupillo, G.; Rossi Alvarez, C.; Sarchiapone, L.; Sciacca, G.; Skliarova, H.
File in questo prodotto:
File Dimensione Formato  
105_B_109_B104.pdf

solo gestori archivio

Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 501.3 kB
Formato Adobe PDF
501.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2434276
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact